Gupta Aditya K, Browne Melanie, Bluhm Robyn
Department of Medicine, Sunnybrook and Women's College Health Science Center (Sunnybrook site) and the University of Toronto, Toronto, Canada.
J Cutan Med Surg. 2002 Nov-Dec;6(6):554-60. doi: 10.1007/s10227-001-0134-6. Epub 2002 Oct 9.
Imiquimod (Aldara) is an immune response modifier used primarily to treat anogenital warts. Imiquimod induces cytokines and enhances cell-mediated cytolytic antiviral activity in vivo. It exhibits antiviral and antitumor effects; however, it does not exhibit direct antiviral effects in vitro. By inducing cytokines, such as interferon a, imiquimod stimulates both the innate immune response and the cellular arm of acquired immunity. Currently, imiquimod is approved for use in the treatment of external genital and perianal warts in adults.
Beyond its established use, there are case reports and preliminary studies suggesting the effectiveness of imiquimod 5% cream in the treatment of nongenital human papillomavirus warts, molluscum contagiosum, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, Bowen's disease, nongenital human papillomavirus infection, and vulvar intraepithelial neoplasia.
咪喹莫特(艾达乐)是一种免疫反应调节剂,主要用于治疗肛门生殖器疣。咪喹莫特可诱导细胞因子产生,并在体内增强细胞介导的溶细胞抗病毒活性。它具有抗病毒和抗肿瘤作用;然而,它在体外不表现出直接的抗病毒作用。通过诱导细胞因子,如干扰素α,咪喹莫特可刺激先天性免疫反应和获得性免疫的细胞部分。目前,咪喹莫特已被批准用于治疗成人的外生殖器和肛周疣。
除了其已确定的用途外,有病例报告和初步研究表明,5%咪喹莫特乳膏在治疗非生殖器人乳头瘤病毒疣、传染性软疣、光化性角化病、基底细胞癌、鳞状细胞癌、鲍温病、非生殖器人乳头瘤病毒感染和外阴上皮内瘤变方面有效。